細胞訊號傳達的全球市場:現狀分析與預測(2022年～2028年)

全球細胞訊號傳達的市場規模，在預測期間內預計以約8.5％的年複合成長率成長。慢性疾病的發生率上升，細胞為基礎的研究設備的技術進步，對含單一細胞分析、體細胞研究、細胞訊號傳達的細胞為基礎的研究舉措的政府輔助，促進市場成長。

本報告提供全球細胞訊號傳達市場的相關調查，市場洞察，市場趨勢，競爭模式，企業概要等全面性資訊。

目錄

第1章 市場簡介

• 市場定義
• 主要的目標
• 相關利益者
• 限制

第2章 調查手法或假設

• 細胞訊號傳達市場調查流程
• 細胞訊號傳達市場調查手法
• 受訪者簡介

第3章 市場摘要

第4章 摘要整理

第5章 COVID-19對細胞訊號傳達市場的影響

第6章 細胞訊號傳達市場收益(10億美元)(2020年～2028年)

第7章 市場洞察:各產品

• 消耗品
• 設備

第8章 市場洞察:各類型

• 內分泌訊號傳達
• 旁分泌訊號傳達
• 自分泌訊號傳達
• 接觸分泌訊號傳達
• 其他

第9章 市場洞察:各技術

• 流式細胞技術
• 西方印漬術
• ELISA
• 顯微鏡檢驗
• 其他

第10章 市場洞察:各途徑

• AKT訊號傳達途徑
• AMPK訊號傳達途徑
• ErbB/HER訊號傳達途徑
• 其他

第11章 市場洞察:各地區

• 北美
  • 美國
  • 加拿大
  • 其他的北美
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他的歐洲
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他的亞太地區
• 全球其他地區

第12章 細胞訊號傳達的市場動態

• 推動市場要素
• 市場課題
• 影響分析

第13章 細胞訊號傳達的市場機會

第14章 細胞訊號傳達的市場趨勢

第15章 需求面和供給方面的分析

• 需求面分析
• 供給面

第16章 價值鏈分析

第17章 價格分析

第18章 策略性洞察能力

第19章 競爭模式

• 競爭情形
  • 波特的五力分析

第20章 企業概要

• Abcam plc
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Merck KGaA
• QIAGEN
• BD
• Promega Corporation
• Cell Signaling Technology Inc.
• PerkinElmer Inc.
• Danaher

第21章 免責聲明

Cell signaling is the process of cellular communication within the body driven by cells releasing and receiving hormones and other signaling molecules. Cell signaling is a fundamental property of all cellular life in prokaryotes and eukaryotes. Cell signaling is a crucial aspect of biological existence. By enabling cells to sense and react to the extracellular environment, it demonstrates positive benefits that promote growth, development, and immunity. It has several uses in both science and medicine, including the treatment of diabetes, autoimmune, and cancer. The rising incidence of chronic diseases and technological advancements in cell-based research instruments are driving market growth. As per the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), in 2022, Six in ten Americans live with at least one chronic disease, like heart disease and stroke, cancer, or diabetes.

The Cell Signaling Market is expected to grow at a steady rate of around 8.5% owing to the availability of funding for cell-based research. Cell-based research initiatives including single-cell analysis, somatic cell research, and cell signaling are being encouraged and supported by the governments of numerous nations. According to the National Institutes of Health (NIH), an estimated USD 45 billion was granted for stem cell research in the fiscal year 2021.

Based on product, the market is segmented into consumables and instruments. The consumables category held a significant market share in 2020. This is mainly due to their augmented implementations in diagnostic and research fields. Moreover, the overview of multiplex probes and reagents for precise applications in diagnostics as well as drug discovery is anticipated to increase the growth opportunities of this segment in research laboratories and small peripheral laboratories.

Based on type, the market is segmented into endocrine signaling, paracrine signaling, autocrine signaling, juxtacrine signaling, and others. Endocrine signaling is expected to grow with a significant CAGR during the forecast period. Almost all of our daily actions are coordinated by the endocrine system, which regulates cell-cell communication. Numerous prevalent disorders, including diabetes, high blood pressure, and obesity, are characterized by abnormalities in hormones, receptors, and cell signaling pathways. d.

On the basis of technology, the market is categorized into flow cytometry, western blotting, ELISA, microscopy, and others. Among these, flow cytometry held a significant market share in 2020. The flow cytometer facilitates the evaluation of physical and chemical characteristics of thousands of particles and is majorly used in the diagnosis of health disorders, such as cancer, HIV AIDS, and immunological disorders.

Based on pathways, the cell signaling market has been classified into AKT signaling pathway, AMPK signaling pathway, ErbB/HER signaling pathway, and others. The AKT signaling pathway is expected to grow with a significant CAGR during the forecast period. AKT pathway promotes the survival and proliferation of tumor cells in many human cancers and metabolism by activating its downstream effectors. According to the World Health Organization, in 2022, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.

For a better understanding of the market adoption of the cell signaling market, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the increasing p. The expanding R&D in cell anatomy and physiology is a major driver of this sector's growth. According to the National Bureau of Statistics of China, China's social Research and Experimental Development (R&D) investment in 2021 reached 2.7864 trillion yuan, an increase of 14.2 percent over the previous year. The cell signaling market in the Asia Pacific region is indirectly being supported by robust government initiatives, existing projects, and the availability of funding in rising economies.

Some of the major players operating in the market include: Abcam plc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck KGaA, QIAGEN, BD, Promega Corporation, Cell Signaling Technology Inc., PerkinElmer Inc., Danaher.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Cell Signaling Market
• 2.2. Research Methodology of the Cell Signaling Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CELL SIGNALING MARKET

6 CELL SIGNALING MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY PRODUCT

• 7.1. Consumables
• 7.2. Instruments

8 MARKET INSIGHTS BY TYPE

• 8.1. Endocrine Signaling
• 8.2. Paracrine Signaling
• 8.3. Autocrine Signaling
• 8.4. Juxtacrine Signaling
• 8.5. Others

9 MARKET INSIGHTS BY TECHNOLOGY

• 9.1. Flow Cytometry
• 9.2. Western Blotting
• 9.3. ELISA
• 9.4. Microscopy
• 9.5. Others

10 MARKET INSIGHTS BY PATHWAY

• 10.1. AKT Signaling Pathway
• 10.2. AMPK Signaling Pathway
• 10.3. ErbB/HER Signaling Pathway
• 10.4. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. The U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. The U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 CELL SIGNALING MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 CELL SIGNALING MARKET OPPORTUNITIES

14 CELL SIGNALING MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 PRICING ANALYSIS

18 STRATEGIC INSIGHTS

19 COMPETITIVE SCENARIO

• 19.1. Competitive Landscape
  • 19.1.1. Porters Fiver Forces Analysis

20 COMPANY PROFILED

• 20.1. Abcam plc
• 20.2. Thermo Fisher Scientific Inc.
• 20.3. Bio-Rad Laboratories Inc.
• 20.4. Merck KGaA
• 20.5. QIAGEN
• 20.6. BD
• 20.7. Promega Corporation
• 20.8. Cell Signaling Technology Inc.
• 20.9. PerkinElmer Inc.
• 20.10. Danaher

21 DISCLAIMER